Flora Peyvandi/X
Oct 21, 2025, 06:43
Could Gene Therapy Offer Lasting Quality of Life for People with Hemophilia B?
Flora Peyvandi, Professor of Internal Medicine-Hemostasis and Thrombosis Unit, University of Milan, former President of ISTH, shared on X.
”Health-related quality of life in adults with hemophilia B after gene therapy with fidanacogene elaparvovec. Results from the BENEGENE-2 trial.”
Read more here.
Stay updated with Hemostasis Today.
-
Jan 23, 2026, 17:17Michael Makris on Japan’s Breakthrough FVIII Variants for Hemophilia A
-
Jan 23, 2026, 17:06Wolfgang Miesbach: HOPE-B Challenges 20 Years of Exclusion Criteria
-
Jan 23, 2026, 16:56Oliver Tiebel: Great and Unique Compilation of Current Knowledge on VWD
-
Jan 23, 2026, 16:46Soumya Mukherjee on Amyloid-β Isoform Modifications in CAA and Alzheimer’s
-
Jan 23, 2026, 16:32Amit Srivastava Edits The New Springer Protocols Volume on Extracellular Vesicles
-
Jan 23, 2026, 14:42David Stegner on PITTs Exacerbating Severe Inflammation
-
Jan 23, 2026, 14:30Christian Schulze: Time to Say Good-Bye to The “Obesity Paradox”?
-
Jan 23, 2026, 14:16Ahmed Nasreldein In The 1st Podcast Episode of International Journal of Stroke
-
Jan 23, 2026, 13:53Omar Shaltout: When Hematology Meets Gastroenterology in the ICU